approval
saveGLYXAMBI (EMPAGLIFLOZIN) — FDA approval
community read0 votes
Sponsor: BOEHRINGER INGELHEIM. Form: TABLET. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalGLYXAMBI (EMPAGLIFLOZIN) — FDA approvalOct 30, 2023 · 1067d ago
- approvalGLYXAMBI (EMPAGLIFLOZIN) — FDA approvalOct 13, 2022 · 1449d ago
- approvalGLYXAMBI (EMPAGLIFLOZIN) — FDA approvalMar 21, 2022 · 1655d ago
- approvalGLYXAMBI (EMPAGLIFLOZIN) — FDA approvalJun 11, 2021 · 1938d ago
- approvalGLYXAMBI (EMPAGLIFLOZIN) — FDA approvalJun 11, 2021 · 1938d ago
- approvalGLYXAMBI (EMPAGLIFLOZIN) — FDA approvalMar 30, 2020 · 2376d ago
- approvalGLYXAMBI (EMPAGLIFLOZIN) — FDA approvalJan 24, 2020 · 2442d ago
- approvalGLYXAMBI (EMPAGLIFLOZIN) — FDA approvalJul 3, 2019 · 2647d ago
same company · ±60 days · 6
- approval(empagliflozin + linagliptin + metformin hydrochloride) ER: TRIJARDY XR (EMPAGLIFLOZIN) — FDA approvalOct 24, 2025
- approvalSYNJARDY: JARDIANCE (EMPAGLIFLOZIN) — FDA approvalOct 24, 2025
- approval(empagliflozin + metformin hydrochloride ER): SYNJARDY XR (EMPAGLIFLOZIN) — FDA approvalOct 24, 2025
- approvalSYNJARDY: SYNJARDY (EMPAGLIFLOZIN) — FDA approvalOct 24, 2025
- approvalspesolimab: SPEVIGO (SPESOLIMAB-SBZO) — FDA approvalOct 21, 2025
- approvalCYLTEZO: CYLTEZO (ADALIMUMAB-ADBM) — FDA approvalOct 16, 2025
comments(0)
5-min edit window · permanent after that